iRhythm Holdings shares fell even after the company posted beat-and-raise results, according to the Carillon Eagle Small Cap Growth Fund's first-quarter 2026 investor letter. The fund cited broader weakness in the healthcare equipment and supplies industry as investors rotated into cyclical and technology stocks. Additional pressure came from a US Department of Justice Civil Investigative Demand received in December related to mobile cardiac telemetry services rendered in 2023 via iRhythm's Zio AT device, though the inquiry is limited in scope and accounts for only a small portion of total sales. The fund noted the risk has already been priced in and did not read much into the company's recent change of auditors. iRhythm Holdings closed at $112.47 per share on June 24, 2026, with a one-month return of negative 2.72% and a 52-week loss of 26.34%.
iRhythm Technologies IncUS DOJ Civil Investigative Demand related to Zio AT device adds regulatory risk.